Navigation Links
Actavis Launches Generic KADIAN® Capsules in the U.S.
Date:11/11/2011

MORRISTOWN, N.J., Nov. 11, 2011 /PRNewswire/ -- Actavis, an international generic pharmaceutical company, today announced that it has begun shipping Morphine Sulfate Extended-Release Capsules, USP CII, an authorized generic of KADIAN®*.

Actavis has been manufacturing KADIAN® for 15 years and has in-depth expertise in the development and manufacturing of complex controlled-release pharmaceuticals.  

KADIAN® US sales have grown 50% in the last 5 years to approximately $275 million for the 12 months ending September 30, 2011, according to IMS Health.  

Please see full prescribing information at www.actavis.us/morphinesulfate

About Actavis:

Actavis Inc. is the U.S. subsidiary of Actavis Group hf. Approximately one third of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis has U.S. manufacturing and packaging facilities in Elizabeth, NJ; a manufacturing facility in Lincolnton, NC; and research and development facilities in Owings Mills, MD and Sunrise, FL. Please visit www.actavis.us for more information.

*KADIAN ® is a registered trademark of Actavis Elizabeth LLC.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis.  By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.


'/>"/>
SOURCE Actavis Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis Plans Latin America Expansion
2. Actavis Launches Generic Keppra XR® Tablets in the U.S.
3. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
4. Actavis Launches Oxymorphone Hydrochloride Extended-Release Tablets, CII in the U.S.
5. Actavis Hails U.S. Supreme Court Decision in Labeling Cases
6. Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV in the U.S.
7. Actavis Receives FDA Approval of Donepezil Hydrochloride Tablets in the U.S.
8. Actavis Receives Approval of Valacyclovir Hydrochloride Tablets in the U.S.
9. Actavis Receives Approval of Pantoprazole Sodium Delayed-Release Tablets, USP in the U.S.
10. Actavis Encourages Consumers to Return Fentanyl Transdermal System 25 mcg/h
11. Actavis Inc. Issues a Voluntary Recall of 18 Lots of Fentanyl Transdermal System 25 mcg/h
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... , May 9, 2017  Semler Scientific, Inc. ... technology solutions to improve the clinical effectiveness and ... for the first quarter ended March 31, 2017. ... enable our customers to identify when preventive care ... before events like heart attacks or strokes occur," ...
(Date:5/6/2017)... --  Provista , a proven leader in the supply chain ... Jim Cunniff as the company,s new president and ... to Provista, including most recently serving as the president and ... . He assumed his new role with Provista on May ... Provista," says Jody Hatcher , president, Sourcing and Collaboration ...
(Date:5/4/2017)... MONTREAL , May 4, 2017  Fortuna Fix Inc. (" ... aiming to be the first to eliminate the need for ... autologous cells to treat neurodegenerative diseases. Fortuna ... ("SAB") with Professor Michael Fehlings , MD, PhD; Father ... Hack , MD, MPH; and Professor James Giordano , ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD is dual ... City. He is known for his distinguished expertise and experience in the diagnosis and ... sub-specialty training in treating renovascular disease and aortic aneurysm . He is known ...
(Date:5/24/2017)... ... May 24, 2017 , ... NucleusHealth ... interpretation, has received U.S. Food and Drug Administration (FDA) 510(k) clearance ... and secure cloud platform for medical image management. At the core is patented ...
(Date:5/24/2017)... ... 2017 , ... Dr. Manju R. Kejriwal, a leading Ohio dentist, is now ... a referral. Dr. Kejriwal understands the emotional and financial toll traditional orthodontics can take ... Patients no longer need to feel the esthetic effects of wires and brackets when ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... Policy Solutions is vehemently opposed to Donald Trump’s budget, “A New Foundation for ... that inspires fear, demonizes the poor, marginalizes underserved populations, undermines productivity, and destroys ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... Course II of the HP3 (High-Performance Periodontal Practice) continuing education (CE) series. As ... latest advancements in his field by attending numerous CE courses each year. His ...
Breaking Medicine News(10 mins):